Key Points
- Guardant Health director Alex Azar II sold 69 shares at an average price of $159.89, totaling $11,032.41. The Rule 10b5-1 transaction reduced his holdings by 7.17% to 893 shares.
- Guardant Health recently reported stronger-than-expected results, with quarterly revenue of $334.98 million—up 44.3% year over year—and an adjusted loss of $0.42 per share versus the $0.76 consensus loss.
- Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $190.00; institutional investors own approximately 92.6% of the company.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Alex Azar II sold 69 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $159.89, for a total value of $11,032.41. Following the completion of the sale, the director owned 893 shares of the company's stock, valued at approximately $142,781.77. This trade represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Up 1.8%
NASDAQ:GH opened at $165.88 on Friday. The firm's fifty day simple moving average is $168.14 and its 200 day simple moving average is $139.02. The stock has a market cap of $22.26 billion, a P/E ratio of -47.53 and a beta of 1.58. Guardant Health, Inc. has a twelve month low of $64.00 and a twelve month high of $191.05.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The firm's revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.44) EPS. On average, analysts expect that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
GH has been the subject of a number of recent research reports. Mizuho lifted their price objective on Guardant Health from $175.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Canaccord Genuity Group boosted their target price on Guardant Health from $135.00 to $205.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. TD Cowen reissued a "buy" rating on shares of Guardant Health in a research note on Tuesday, August 25th. Stifel Nicolaus raised their price target on Guardant Health from $130.00 to $180.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, BTIG Research restated a "buy" rating and set a $195.00 price target on shares of Guardant Health in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Guardant Health has a consensus rating of "Moderate Buy" and a consensus target price of $190.00.
Check Out Our Latest Research Report on Guardant Health
Institutional Trading of Guardant Health
A number of institutional investors have recently made changes to their positions in GH. MCF Advisors LLC boosted its holdings in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company's stock valued at $26,000 after acquiring an additional 151 shares during the last quarter. NFSG Corp purchased a new position in shares of Guardant Health during the third quarter valued at approximately $33,000. Ascentis Independent Advisors purchased a new position in shares of Guardant Health during the first quarter valued at approximately $38,000. Hollencrest Capital Management purchased a new position in shares of Guardant Health during the first quarter valued at approximately $41,000. Finally, TrinityBridge Ltd bought a new position in Guardant Health during the second quarter valued at approximately $45,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor's molecular characteristics.
The company's products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
